Asahi Kasei Corporation

Asahi Kasei Corporation

19.98
USD
-0.42
(-2.06%)
1.89EPS
11.45P/E
13.99BMarket Cap
Feb 10Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
2,717.88
2,845.67
2,781.04
2,698.24
2,927.22
3,111.39
3,101.3
3,037.86
3,550.55
3,934.61
4,020.68
4,410.34
4,532.68
4,856.49
Basic EPS, GAAP
145.07
151.35
131.47
164.79
244.03
211.47
149.8
115.06
233.52
-132.69
63.25
196.02
234.11
288.52
Free Cash Flow per Basic Share
211.45
62.96
172.95
110.58
220.19
125.02
-43.23
149.13
19.57
-117.4
178.08
121.32
135.71
33.22
Dividend per Share
28.02
38.03
40.03
40.03
56.05
74.08
70.23
66.06
68.07
70.1
72.13
72.55
80.18
84.61
Book Value per Share
1,307.23
1,551.22
1,492.95
1,649.89
1,845.54
1,980.44
1,960.78
2,116.73
2,434.4
2,397.4
2,618.27
2,740.28
3,081.52
3,129.03
Tangible Book Value per Share
937.1
1,141.33
784.26
986.73
1,251.16
1,220.68
929.06
1,115.15
1,227.1
1,334.42
1,528.55
1,368.9
1,727.21
1,575.9
Basic Weighted Avg Shares
698
698
698
698
698
698
694
693
693
693
693
689
678
675
Sales/Revenue/Turnover
1,897,766
1,986,405
1,940,914
1,882,991
2,042,216
2,170,403
2,151,646
2,106,051
2,461,317
2,726,485
2,784,878
3,037,312
3,074,505
3,277,746
Operating Margin (%)
7.55
7.95
8.51
8.46
9.72
9.66
8.24
8.16
8.23
4.68
5.05
6.98
7.52
8.82
Depreciation Expense
94,875
95,378
109,632
109,193
113,463
104,046
118,304
133,272
148,129
177,286
182,196
186,106
196,344
207,990
Net Income, GAAP
101,297
105,652
91,753
115,001
170,248
147,512
103,931
79,768
161,880
-91,947
43,806
134,997
158,794
194,726
Effective Tax Rate (%)
37.69
32.53
36.19
25.87
21.13
28.79
32.2
45.6
23.84
- -
- -
27.85
23.8
28.08
Profit Margin (%)
5.34
5.32
4.73
6.11
8.34
6.8
4.83
3.79
6.58
-3.37
1.57
4.44
5.16
5.94
Working Capital
313,619
384,130
130,356
299,665
349,801
369,540
264,899
433,613
410,359
576,032
735,465
804,840
1,072,214
989,452
LT Debt
188,482
171,619
135,169
213,051
163,528
230,131
292,678
434,325
422,500
607,950
656,655
876,747
871,962
913,265
Total Equity
925,767
1,097,722
1,057,400
1,168,115
1,305,213
1,402,710
1,383,461
1,494,534
1,718,816
1,695,383
1,848,625
1,913,944
2,165,648
2,165,964
Return on Invested Capital (%)
7.15
8.03
7.23
7.55
9.71
8.55
6.07
4.36
6.52
- -
- -
5.14
5.57
6.39
Return on Capital (%)
8.43
8.2
6.43
7.58
10.82
8.64
5.35
3.73
6.99
- -
- -
4.61
5.2
6.19
Return on Common Equity (%)
11.75
10.59
8.64
10.49
13.96
11.05
7.58
5.64
10.26
-5.49
2.52
7.35
8.04
9.77

Capital Structure

JPY

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
139,259
325,391
306,673
LT Borrowings
837,618
889,753
878,519
LT Finance Leases
34,344
33,825
34,746
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
678
673
666
Market Capitalization
2,096,073
2,415,519
2,202,111

Working Capital

JPY

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
1,865,357
1,974,775
1,966,740
Cash, Cash Equivalents & STI
377,023
387,356
355,853
Accounts Receivable, Net
513,807
525,669
539,697
Inventories
793,725
869,946
900,355
Total Current Liabilities
793,143
983,621
977,288
Payables & Accruals
- -
- -
- -
ST Debt
139,259
325,391
306,673
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.57%
7.87%
13.15%
Free Cash Flow
-161.98%
-212.08%
10.18%
Net Income, GAAP
3.15%
4.86%
17.63%
Sales/Revenue/Turnover
4.88%
8.01%
1.22%
Total Cash Common Dividend
- -
- -
8.85%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
735,934
754,400
768,918
778,060
3,037,312
2026
738,321
748,047
774,895
813,242
3,074,505
2027
826,157
863,452
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
49.23
37.74
55.3
53.78
196.02
2026
29.06
68.55
80.06
56.3
234.11
2027
79.51
72.67
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
36.07
- -
36.14
- -
72.55
2026
40.08
- -
40.06
- -
80.18
2027
44.23
- -
- -
- -
- -

Company Description

CEO
Koshiro Kudo
Full Time Employees
47,895
Sector
Process industries
Industry
Chemicals: specialty
Address
Hibiya Mitsui Tower Tokyo TY Japan 100-0006
IPO Date
May 16, 1949
Business
Asahi Kasei Corp. (3407.T) manufactures and sells advanced materials, homes, and healthcare products worldwide. The company operates through three primary business sectors: Materials, which encompasses basic chemicals, performance products including fibers and engineering plastics such as LEONA polyamide resin and TENAC polyacetal, specialty solutions, and electronics components like Hall effect sensors, lithium-ion battery separators under the Hipore brand, and semiconductor materials; Homes, centered on Hebel Haus unit homes, Hebel autoclaved aerated concrete panels, Neoma Foam phenolic foam insulation, foundation systems, and steel-frame structural components; and Healthcare, providing medical devices for blood purification and transfusion such as Planova virus removal filters, critical care equipment including defibrillators and automated CPR systems, pharmaceuticals in orthopedics and urology, bioprocess products, and diagnostic reagents. Founded in 1931 and headquartered in Tokyo, Japan, Asahi Kasei maintains manufacturing facilities and sales operations across Japan, North America, Europe, Asia, and other regions, serving industries including automotive, construction, electronics, and medical care. In recent developments, the company divested its Daramic lead-acid battery separator business to Kingswood Capital Management on December 1, 2025, as part of its medium-term management plan "Trailblaze Together" to enhance capital efficiency and focus on growth areas like pharmaceuticals, critical care, overseas homes, and electronics; announced an absorption-type merger on December 2, 2025, between its wholly owned subsidiary Asahi Kasei Advance and Teijin Frontier, forming a joint venture effective October 1, 2026, with Asahi Kasei holding 20% to integrate business platforms in sustainable fibers; completed the acquisition of Calliditas Therapeutics AB in September 2024, bolstering its global specialty pharmaceuticals presence in renal and autoimmune diseases; and acquired shares in R.C. Core Co., Ltd. through Asahi Kasei Homes in October 2025.

Company News

  • Asahi Kasei, Circularise, and Furuya Metal Launch Demonstration Project for Precious Metal Traceability in Chlor-Alkali Electrolysis Electrodes

  • Asahi Kasei Signs MOU With Power to Hydrogen to Accelerate Commercialization of AEM Water Electrolysis for Clean Hydrogen Production

  • Asahi Kasei (OTCMKTS:AHKSY) Stock Price Down 4.5% – Should You Sell?

  • Asahi Kasei Corp. (OTCMKTS:AHKSY) Sees Large Increase in Short Interest

  • Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults

  • US FDA approves Asahi Kasei's drug for persistent herpes infections

  • Asahi Kasei Microdevices Holds IEEE Milestone Commemoration Ceremony in Nobeoka for the Commercialization of Thin-Film Hall Elements

  • Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients

  • Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics

  • Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing

  • Asahi Kasei Microdevices' CZ39 and CZ3K Current Sensors Featured in Microchip Technology's Machine Learning-Based Arc Fault Detection Reference Design

  • Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company's 40-Year North American Battery Separator Strategy

  • Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries

  • Asahi Kasei's Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives

  • Asahi Kasei Enters First License Agreement for Production and Sale of Acetolyte™ Novel Electrolyte in China

  • Asahi Kasei's Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time

  • Asahi Kasei Develops Novel Photosensitive Polyimide Film for Advanced Panel-Level Semiconductor Packaging

  • Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030

  • Best Value Stocks to Buy for April 30th

  • New Strong Buy Stocks for April 30th